Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

329 ARTÍCULOS , VIENDO DEL 91 AL 105

Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates

Viayna E, Sabate R, Muñoz-Torrero D.

Curr Top Med Chem. 2013;13(15):1820-42. doi: 10.2174/15680266113139990139.

Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease

Martinez A, Perez DI, Gil C.

Curr Top Med Chem. 2013;13(15):1808-19. doi: 10.2174/15680266113139990138.

The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors

Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, Brindisi M, Gemma S.

Curr Top Med Chem. 2013;13(15):1787-807. doi: 10.2174/15680266113139990137.

Multifunctional tacrine derivatives in Alzheimer's disease

Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V.

Curr Top Med Chem. 2013;13(15):1771-86. doi: 10.2174/15680266113139990136.

New approaches to the treatment of Alzheimer's disease

Rampa A, Bisi A.

Curr Top Med Chem. 2013;13(15):1743-4. doi: 10.2174/15680266113139990134.

Successes and failures for drugs in late-stage development for Alzheimer's disease

Berk C, Sabbagh MN.

Drugs Aging. 2013 Oct;30(10):783-92. doi: 10.1007/s40266-013-0108-6.

Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep

Song HR, Woo YS, Wang HR, Jun TY, Bahk WM.

Int Clin Psychopharmacol. 2013 Nov;28(6):346-8. doi: 10.1097/YIC.0b013e328364f58d.

Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies

Liu YH, Zeng F, Wang YR, Zhou HD, Giunta B, Tan J, Wang YJ.

Drug Discov Today. 2013 Dec;18(23-24):1212-20. doi: 10.1016/j.drudis.2013.07.020. Epub 2013 Aug 13.

Overload of families taking care of elderly people with Alzheimer's Disease: a comparative study

Borghi AC, de Castro VC, Marcon SS, Carreira L.

Rev Lat Am Enfermagem. 2013 Jul-Aug;21(4):876-83. doi: 10.1590/S0104-11692013000400007.

Human Vaccines & Immunotherapeutics. Letter from the editor

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Aug;9(8):1609-10. doi: 10.4161/hv.26188. Epub 2013 Aug 1.

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease

Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C.

Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):583-91. doi: 10.1177/1533317513495104.

The therapeutics of Alzheimer's disease: where we stand and where we are heading

Selkoe DJ.

Ann Neurol. 2013 Sep;74(3):328-36. doi: 10.1002/ana.24001.

Memantine-associated hyperkalaemia in a patient with Alzheimer's disease

Tsukamoto T, Yamada H, Uchimura N.

Psychogeriatrics. 2013 Sep;13(3):180-1. doi: 10.1111/psyg.12022.

ETNA3, a clinical randomized study assessing three cognitive-oriented therapies in dementia: rationale and general design

Amieva H, Dartigues JF.

Rev Neurol (Paris). 2013 Oct;169(10):752-6. doi: 10.1016/j.neurol.2013.07.011. Epub 2013 Sep 4.

Anti-neuroinflammatory agents for the treatment of Alzheimer's disease

Zhou W, Hu W.

Future Med Chem. 2013 Sep;5(13):1559-71. doi: 10.4155/fmc.13.125.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias